Are we there yet? CAR‐T therapy in multiple myeloma Authors: Eitan Mirvis, Reuben Benjamin Published: 2024 ABSTRACT SummaryThe last few years have seen a revolution in cellular immunotherapies for multiple myeloma (MM) with novel antigen targets. The principle new target is B‐cell maturation antigen (BCMA). Autologous chimeric antigen receptor T‐cell (CAR‐T) therapy directed against BCMA was first approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) in 2021, although approval by the National Institute for Health and Care Excellent (NICE) is awaited. Initial response rates in patients with heavily pretreated MM have been impressive, but patients are still relapsing. Furthermore, CAR‐T manufacturing is expensive and time‐consuming, and T‐cell fitness is impaired by prior MM treatment. Numerous strategies to improve outcomes and delivery of cellular immunotherapy are under investigation, including next‐generation CARs, allogeneic ‘off‐the‐shelf’ CARs and targeting of other MM antigens including G protein‐coupled receptor, class C, group 5, member D (GPRC5D), Fc receptor homologue 5 (FcRH5), cluster of differentiation (CD)19, signalling lymphocyte activation molecule family member 7 (SLAMF7) and several others. In this exciting and rapidly evolving treatment landscape, this review evaluates the most recent clinical and preclinical data pertaining to these new cellular immunotherapies and explores strategies to overcome resistance pathways. On the protracted journey to a long‐term cure, we outline the challenges that lie ahead and ask, ‘Are we there yet?’ INTRODUCTION Multiple myeloma (MM) is a clonal plasma cell (PC) neoplasm characterised by features of end‐organ damage including hypercalcaemia, renal insufficiency, anaemia and lytic bone lesions. 1 Median overall survival (OS) ranges from 7 to 10 years in standard‐risk patients to 3 years in patients with high‐risk cytogenetic abnormalities such as t(4;14), t(14;16), t(14;20) and del(17/17p). 2 In the MAMMOTH study, median OS was only 9.2 months in patients triple refractory to a proteasome inhibitor (PI), immunomodulatory drug (IMiD) and anti‐cluster of differentiation (CD)38 monoclonal antibody (CD38 mAb). 3 Second autologous stem cell transplant (ASCT) has limited efficacy; 975 patients salvaged with second ASCT had cumulative incidence of relapse/progression of 49% at 1 year and 84% at 3 years. 4 Outcomes of allogeneic SCT in MM are generally poor, with 1‐year transplant‐related mortality at 23.5% and 5‐year OS at 22.2%. 5 There is, therefore, an urgent need for treatment with long‐term curative potential for relapsed/refractory MM (RRMM). Novel therapeutic strategies include bispecific T‐cell engagers (BiTEs) and chimeric antigen receptor T‐cell (CAR‐T) therapy. BiTEs consist of two antigen recognition domains connected via a linker. They create an indirect immunological synapse between MM cells and T‐cells, resulting in T‐cell activation and MM cell death. 6 BiTEs targeting B‐cell maturation antigen (BCMA), G protein‐coupled receptor, class C, group 5, member D (GPRC5D) and Fc receptor homologue 5 (FcRH5) have been developed and are reviewed elsewhere. 7 , 8 , 9 CAR‐T therapy involves reprogramming T cells with a CAR construct targeting a tumour‐associated antigen. Antigen binding triggers CAR‐T activation, proliferation and cytotoxic effector functions. First approved in 2017, CD19 CAR‐T now plays a transformative role in relapsed/refractory B‐cell acute lymphoblastic leukaemia, large B‐cell lymphomas and mantle cell lymphoma. 10 More recently, CARs have been manufactured against MM tumour antigens, including BCMA, GPRC5D and several others. In addition to an intracellular CD3ζ signal transduction domain, second‐generation CARs are equipped with a costimulatory domain, for example, CD28 or 4‐1BB, which improves proliferation, cytokine secretion, resistance to apoptosis and persistence. 11 All currently licensed CARs are second generation. Third‐generation CARs have two costimulatory domains, usually CD28 combined with 4‐1BB. Fourth‐/next‐generation CARs have further modifications, including armoured CAR‐T cells, which overpower the inhibitory tumour microenvironment (TME), and T cells redirected for universal cytokine‐mediated killing (TRUCKs), which express cytokines to promote CAR‐T function and survival. 12 CAR‐T manufacture begins with leukapheresis; T cells are subsequently activated and transduced with a viral vector encoding the CAR, resulting in CAR expression on the T‐cell surface. Following CAR‐T expansion, the product is concentrated and cryopreserved. 13 Prior to CAR‐T infusion, the recipient requires lymphodepletion, usually with fludarabine and cyclophosphamide. 14 The most common CAR‐T toxicity is cytokine release syndrome (CRS), a state of immune over‐activation associated with CAR‐T expansion. Grade 1 CRS involves fever; however, symptoms can rapidly progress to multiorgan failure. In addition to supportive care, severe CRS is treated with tocilizumab (anti‐IL‐6 mAb) and if refractory, corticosteroids. Immune effector cell‐associated neurotoxicity syndrome (ICANS) can range from mild confusion to seizures to fatal cerebral oedema. The mechanism is poorly understood. 15 Other common toxicities include cytopaenias and infection. This review will discuss the novel cellular immunotherapy targets being explored in RRMM, with an emphasis on strategies to overcome resistance and improve depth and duration of response. NOVEL IMMUNOTHERAPY TARGETS BCMA BCMA (CD269) is a pro‐survival non‐tyrosine kinase receptor surface glycoprotein and a member of the tumour necrosis factor receptor (TNFR) superfamily (Figure 1). Expression is restricted to late memory B cells and PCs and is highest in MM cells. BCMA transmits downstream signals which are important for PC survival. 16 Novel cellular immunotherapy targets in multiple myeloma (MM). The γ‐secretase complex cleaves B‐cell maturation antigen (BCMA) from the MM cell surface, releasing soluble BCMA (sBCMA) into the bloodstream. APRIL is one of the two natural ligands for BCMA and TACI. Created in BioRender. Mirvis, E. (2024) https://BioRender.com/r05s346. BCMA CAR‐T has shown impressive results in heavily pretreated MM. A meta‐analysis of 21 trials including total of 761 RRMM patients showed overall response rate (ORR) of 87%, complete response rate (CRR) of 44%, median progression‐free surviv (PFS) of 8.77 months and median OS of 18.87 months. 17 Idecabtagene vicleucel (Ide‐cel) contains a murine anti‐BCMA single‐chain variable fragment (scFv) with 4‐1BB as the costimulatory domain delivered via a lentiviral vector. In the phase II KarMMa study, 128 patients who progressed after median of six lines of treatment (LOT) attained ORR of 73% and median PFS of 8.8 months (Table 1). 19 There was correlation between depth and duration of response, with duration of 4.5, 10.4 and 19 months for patients attaining partial response (PR), very good PR (VGPR) and CR/stringent CR (sCR) respectively. In phase III KarMMa‐3, which enrolled patients treated with two to four prior LOT, Ide‐cel achieved ORR of 71% compared with 42% in the standard chemotherapy treatment arm; median PFS was 13.3 months versus 4.4 months. Grades 3–4 CRS occurred in 5% and grades 3–4 ICANS in 3% (Table 2). 21 A retrospective study of real‐world data included 196 patients, 75% of whom would have been ineligible for KarMMa due to comorbidities. ORR was 84%, median PFS 8.5 months and median OS 12.5 months. 47 The largest real‐world study of Ide‐cel outcomes includes 603 patients with median of seven prior LOT. ORR was 71%, again comparable with KarMMa and KarMMa‐3. With median follow‐up of 6.6 months, estimated 6‐month PFS was 62% and OS of 82%. 48 Multivariate analysis has identified prior BMCA‐directed therapy, high‐risk cytogenetics and elevated baseline ferritin level as potential predictors of early progression/refractory disease following Ide‐cel. 49 KarMMa‐2 (NCT03601078) is investigating Ide‐cel in clinical high‐risk MM patients at an earlier stage of the disease. Interim results demonstrate ORR of 83.8% and median PFS of 11.4 months in patients who progressed within 18 months of initial ASCT. 20 TABLE 1CAR clinical trials.ReferenceTargetAgent, sourceAuto/alloPhasePrior LOT (median)Enrolment (n)ORR (%)Median PFS (months)Median OS (months)CRS grade ≥3 (%)ICANS grade ≥3 (%)NCT02658929 Raje et al 18 BCMAIde‐cel, murineAutoI3–14 (7)338511.8NR63NCT03361748 KarMMa 19 BCMAIde‐cel, murineAutoII3–16 (6)140738.8NR53NCT03601078 KarMMa‐2 Cohort 2A 20 BCMAIde‐cel, murineAutoII1 ± bridging3983.811.4NR2.70NCT03651128 KarMMa‐3 21 BCMAIde‐cel, murineAutoIII2–4 (3)38671 vs 4213.3 vs 4.4NR53NCT03548207 CARTITUDE‐1 22 BCMACilta‐cel, camelidAutoIb/II≥3 (6)1139734.9NR49NCT04133636 CARTITUDE‐2 Cohort B 23 BCMACilta‐cel, camelidAutoII11888.9NRNR5.60NCT04181827 CARTITUDE‐4 24 BCMACila‐cel, camelidAutoIII1–3 (2)41984.6 vs 67.3NR vs 11.8NR1.10NCT05243212 Magen et al 25 BCMACAR‐BCMA, murineAutoIb/II3–5 (4)3259NRNR30Mikkilenini et al 26 BCMAFHVH‐T, humanAutoI3–10 (6)259215NR248NCT05066646 FUMANBA‐1 27 BCMACT103A, humanAutoIb/II3–23 (4)10396NR (12 month PFS 78.8%)NR1Not reportedNCT04309981 CARTBCMA‐HCB‐01 Interim analysis 28 BCMAARI0002h, humanAutoI/II≥235100NRNR00NCT03975907 LUMMICAR‐1 29 BCMAZevor‐cel, humanAutoII3–15 (4)10292.8NRNR6.90NCT04155749 Frigault et al 30 BCMACART‐ddBCMA, syntheticAutoI3–16 (5)37100NR after median 12.1 monthsNR after median 12.1 months36NCT04093596 UNIVERSAL Part A 31 BCMAALLO‐715, humanAlloI3–11 (5)4355.88 (mDOR)NR20NCT04555551 Mailankody et al 32 GPRC5DMCARH109, humanAutoI4–14 (6)1771N/aN/a612NCT04674813 Part A Bal et al 33 GPRC5DCC‐95266AutoI3–13 (4)1786N/aN/a00NCT05016778 POLARIS 34 GPRC5DOriCAR‐017AutoI≥310100NRNR00Xia et al 35 GPRC5DGPRC5D‐CAR, humanAutoII2–12 (4)3391N/aN/a03Zhou et al 36 BCMA‐GPRC5DMurine BCMA, human GPRC5DAutoI3–5 (3)2186NRNR00Shi et al 37 BCMA + CD19Both murineAutoI110100NR (70% at 2 years)NR00Garfall et al 38 BCMA + CD19CART‐BCMA, huCART19 – both humanAutoIA: ≥3; B: 1A: 10; B: 20A: 100; B: 55A: 5.2; B: 10.3A: 15.9; B: NR00Du et al 39 BCMA‐CD19GC012FAutoI2–9 (5)2993.138NR70NCT04662099 Li et al 40 BCMA‐CS1Both murineAutoI/IIa2–8 (4)16819NR (1 year 73%)60NCT03287804 AUTO2 Lee et al 41 BCMA‐TACIAPRILAutoI3–6 (5)1145.5512.300Mei et al 42 BCMA‐CD38BM38, humanAutoI2–9 (4)238717.2NR (1 year 93%)220Tang et al 43 BCMA‐CD38Not specifiedAutoI2–3 (3)1687.5NR (1 year 69%)NR (1 year 75%)310Zhang et al 44 BCMA + CD38Human BCMA, murine CD38AutoII4–12 (8)2290.948.7% at 24 months56.6% at 24 months27.30Abbreviations: LOT, lines of treatment; mDOR, medium duration of response; NR, not reached. CAR clinical trials. Abbreviations: LOT, lines of treatment; mDOR, medium duration of response; NR, not reached. TABLE 2Grading of common toxicities of cellular immunotherapy.ToxicityGrade 1: MildGrade 2: ModerateGrade 3: SevereGrade 4: Life‐threateningCRSFeverTemp ≥38°CTemp ≥38°CTemp ≥38°CTemp ≥38°CWithHypotensionNoneNot requiring vasopressorsRequiring a vasopressor with or without vasopressinRequiring multiple vasopressors (excluding vasopressin)And/orHypoxiaNoneRequiring low‐flow nasal cannula or blow‐byRequiring high‐flow nasal cannula, facemask, non‐rebreather mask or Venturi maskRequiring positive pressure (e.g., CPAP, BiPAP, intubation and mechanical ventilation)ICANSICE score a 7–93–60–20 (unrousable)Depressed consciousnessAwakens spontaneouslyAwakens to voiceAwakens only to tactile stimulusUnrousable or requires vigorous/repetitive tactile stimuli to arouseSeizureN/aN/aAny clinical seizure focal or generalised that resolves rapidly or non‐convulsive seizures on EEG that resolve with interventionLife‐threatening prolonged seizure (>5 min); or repetitive clinical or electrical seizures without return to baseline in betweenMotor findingsN/aN/aN/aDeep focal motor weakness such as hemiparesis or paraparesisElevated ICP/cerebral oedemaN/aN/aFocal/local oedema on neuroimagingDiffuse cerebral oedema on neuroimaging; decerebrate or decorticate posturing; cranial nerve VI palsy; papilloedema; or Cushing triadMNTAsymptomatic (clinical observation only)/ mild symptomsModerate symptomsSevere symptomsLife‐threatening symptomsAnaemiaHb < LLN (100 g/L)Hb <100–80 g/LHb <80 g/L; transfusion indicatedLife‐threatening anaemiaThrombocytopaenia